Clinical Trials Logo

Endothelial Dysfunction clinical trials

View clinical trials related to Endothelial Dysfunction.

Filter by:

NCT ID: NCT01242306 Completed - Clinical trials for Endothelial Dysfunction

Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions

CREDENTIAL
Start date: March 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, randomised study to compare the endothelial dysfunction of BMS vs SES, both implanted in the same patient with multiple de novo coronary artery lesions undergoing elective PCI. The primary end point will be the evaluation of endothelial dysfunction at 6 months follow-up by measuring the change in vessel diameter in 5 points of the stent and peri-stent site after infusion of acetylcholine.

NCT ID: NCT01223625 Completed - Atherosclerosis Clinical Trials

Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function

Start date: November 2007
Phase: Phase 4
Study type: Interventional

The aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the endothelial function.

NCT ID: NCT01151683 Completed - Hypertension Clinical Trials

Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients

MG600
Start date: March 2010
Phase: Phase 4
Study type: Interventional

Introduction: Magnesium has been the target for many experimental and clinical studies due to the negative correlation between its serum and intracellular levels and the prevalence of hypertension and other cardiovascular diseases. Objective: To evaluate the effects of magnesium supplementation in hypertensive patients who are under diuretic treatment, including correlation of clinical and nutritional parameters with structural and functional aspects of the macrocirculation. Methods: A prospective, randomized, double blind, placebo controlled study will be performed in hypertensive patients, aged between 40 and 65 years-old, in regular use of thiazidic diuretic as antihypertensive monotherapy,. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness. Analysis: Data will be expressed as mean±epm. Statistical analysis will be performed using software Prism® (GraphPad, version 5.0). Continuous variables in each group will be compared using "t test", and P<0.05 will be considered statistically significant.

NCT ID: NCT01137253 Completed - Clinical trials for Endothelial Dysfunction

Autonomic Nervous System and Nitric Oxide Interactions

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The investigators are interested in the role of the autonomic nervous system in the regulation of endothelial function among obese hypertensive subjects. In particular, the investigators will study how endothelial function (response to intra-arterial acetylcholine) changes during autonomic withdrawal.

NCT ID: NCT01125943 Completed - Hypertension Clinical Trials

Bevacizumab and Endothelium Dependent Vasodilation

Start date: June 2010
Phase: N/A
Study type: Interventional

The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most reported side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor, hypertension had an overall incidence up to 32%. The increase in blood pressure occurs early in treatment. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Understanding the pathogenesis of this side effect is essential for optimal treatment with this class of drugs. The primary objective is to explore the effect of bevacizumab infusion on endothelium-dependent vasodilation of forearm resistance arteries.

NCT ID: NCT01084187 Completed - Clinical trials for Erectile Dysfunction

Correlation Study of Vascular Parameters in Hypertensive Men With Erectile Dysfunction

Start date: January 2010
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the correlation of FMD of brachial artery and carotid intima media thickness with ED severity and clinical response to vardenafil in hypertensive men.

NCT ID: NCT01067339 Completed - Clinical trials for Endothelial Dysfunction

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Start date: February 2010
Phase: Phase 3
Study type: Interventional

AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is directly connected to IRB 08-008161 as a specific aim of the National Institute of Health (NIH) grant. Participants may either consent to and qualify for AIM I and AIM II (IRB 08-008161) or have a cardiac catheterization with acetylcholine testing in the Cardiac Catheterization Laboratory at Mayo Clinic in Rochester MN to be considered for this study.

NCT ID: NCT01046682 Completed - HIV Clinical Trials

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Salsalate
Start date: January 2009
Phase: Phase 2
Study type: Interventional

This is a phase II, open label, randomized-controlled pilot study designed to study both the efficacy and safety of salsalate in decreasing endothelial cell dysfunction, systemic inflammation, and insulin resistance in HIV-infected adults. The investigators hypothesis is that salsalate will reduce inflammation and therefore endothelial cell activation and insulin resistance. The sample size will be 40, with an equal number of people being randomized to one of two groups. The first arm will be randomized to salsalate therapy. The second arm will act as a control group. The study duration will be 13 weeks.

NCT ID: NCT01013103 Completed - Clinical trials for Coronary Artery Disease

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

Start date: October 2007
Phase: Phase 4
Study type: Interventional

The present study constitutes a study examining the effect of atorvastatin on vascular function in high cardiovascular risk patients. For this purpose the investigators will record atorvastatin effects on statin-naïve patients (patients that start statins treatment for first time). More specifically the investigators will study atorvastatin effects on: 1. Endothelial function 2. Arterial elastic properties 3. Systemic Inflammatory/thrombotic mechanisms 4. Vascular and myocardial redox state

NCT ID: NCT01000688 Completed - Type 2 Diabetes Clinical Trials

Vildagliptin and Endothelium-dependent Vasodilatation

Start date: January 2010
Phase: Phase 3
Study type: Interventional

Rationale: Cardiovascular complications in type 2 diabetes are the leading cause of morbidity and mortality associated with the disease. Endothelial dysfunction is regarded as an important factor in these vascular complications. The introduction of glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes is of special interest because of possible influences on endothelial function. Numerous reports have shown that GLP-1 improves endothelial function. Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.